Drugs /

pd-1 knockout ebv-specific cytotoxic t lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of Epstein-Barr virus (EBV) reactive cytotoxic T-lymphocytes (CTLs) in which the programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1) gene is deleted, with potential immunomodulating activity. Upon administration of the PD-1 knockout EBV-specific CTLs, these CTLs target and induce selective toxicity in EBV-positive cancer cells. This results in cell lysis and inhibition of cancer cell proliferation. Expression of PD-1, an inhibitory receptor expressed on activated T-cells, plays a key role in CTL suppression, T-cell exhaustion and CTL apoptosis. PD-1 knockout abrogates T-cell exhaustion and increases T-cell activity and cytotoxicity. EBV, a ubiquitous human herpesvirus, is associated with various cancer cell types.

Clinical Trials

View Clinical Trials for pd-1 knockout ebv-specific cytotoxic t lymphocytes

Pd-1 knockout ebv-specific cytotoxic t lymphocytes has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pd-1 knockout ebv-specific cytotoxic t lymphocytes, 1 is phase 1/phase 2 (1 open).

EBV Positive, HLA-A*02 Positive, and HLA-A*11 Positive are the most frequent biomarker inclusion criteria for pd-1 knockout ebv-specific cytotoxic t lymphocytes clinical trials.

Gastric carcinoma, lymphoma, and nasopharyngeal carcinoma are the most common diseases being investigated in pd-1 knockout ebv-specific cytotoxic t lymphocytes clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pd-1 Knockout Ebv-Specific Cytotoxic T Lymphocytes
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pd-1 knockout ebv-specific cytotoxic t lymphocytes and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pd-1 knockout epstein-barr virus cytotoxic t-lymphocytes, pd-1 knockout ebv-reactive ctl, pd-1 knockout ebv-ctl, pd-1 knockout ebv-ctl, pd-1 knockout epstein-barr virus-cytotoxic t-lymphocytes, pd-1 knockout ebv-reactive ctls, pd-1 knockout ebv-ctls
NCIT ID [1]:
C148180

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.